Engene to present details of its pivotal phase 1/2 legend study of eg-70 in bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ at the american urology association 2024 annual meeting

Oral presentation highlights rational design of eg-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations boston and montreal , may 2, 2024 /prnewswire/ - engene holdings inc. (nasdaq: engn) or ("engene" or the "company"), a clinical-stage genetic medicines company whose non-viral lead program eg-70 is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced an oral presentation at the american urology association (aua) 2024 annual meeting being held may 3-6, 2024 in san antonio, texas. the presentation, "legend: a phase 1/2 study of eg-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (cis)," will be given by dr. gordon brown, director of the center for advanced therapeutics and urologic oncology, summit health-south, at 10:30 a.m.
ENGN Ratings Summary
ENGN Quant Ranking